Sodium-Glucose Transport Protein-2 Inhibitors in the Treatment of Nonalcoholic Steatohepatitis: An Evidence-Based Review

2024/11/10 by Dongmei Wang
#Medicine and Health Sciences

paper · doi:10.17605/osf.io/v2y5n

Abstract

This review reported the effectiveness of sodium-glucose transport protein-2 (SGLT-2) inhibitors in the treatment of non-alcoholic steatohepatitis (NASH).

Related

• Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety
• GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
• Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
• First in human randomised trial of J2H ‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment
• Sodium-glucose cotransporter 2 inhibitors and atherosclerosis